Aytu Biopharma (AYTU) 2nd Annual Lytham Partners Healthcare Investor Summit summary

Exxua launch and strategic fit

• Exxua, a novel antidepressant, was acquired through a partnership with Fabre-Kramer Pharmaceuticals, aligning with existing psychiatry-focused infrastructure.

• The launch is seen as a transformative opportunity, leveraging a mature sales force and commercial infrastructure previously focused on ADHD.

• Exxua is the first and only 5-HT1A agonist indicated for major depressive disorder, offering a unique mechanism distinct from SSRIs and SNRIs.

• The sales team is now fully aligned to high-prescribing psychiatrists, with a targeted, efficient approach to market entry.

• Early market feedback and prescription activity are positive, with a focus on brand-centric prescribers.

Product differentiation and market positioning

• Exxua avoids common side effects of traditional antidepressants, such as sexual dysfunction, weight gain, and increased anxiety.

• Demonstrated efficacy in pivotal studies, with a relatively rapid onset of action compared to SSRIs.

• Initial use is expected in later lines of therapy due to payer and clinical guidelines, but potential exists to move earlier as familiarity and access improve.

• Messaging to prescribers emphasizes novel mechanism, efficacy, favorable side effect profile, and patient access.

Commercial infrastructure and RxConnect

• Existing sales force of 40-45 reps, already experienced in psychiatry, is now dedicated to Exxua.

• RxConnect, a proprietary pharmacy network, streamlines access, reduces prior authorization hurdles, and ensures predictable copays for patients.

• The program has proven effective in the ADHD market and is expected to drive Exxua uptake by addressing prescriber concerns about cost and coverage.

• RxConnect covers about 85% of ADHD prescriptions, providing resilience against generic competition.